Previous studies shows that zanubrutinib is more selective and active than ibrutinib in inhibiting BTK activity, with lower off-target activity against the follow protein tyrosine kinases: tyrosine kinase interleukin-2-inducible T-cell kinase (ITK), epidermal growth factor receptor (EGFR), and other kinases expressed in hepatocellular carcinoma (TEC) (10). This evidence concerns the gene ITK and hepatocellular carcinoma.